Sinmeton-500 (nabumetone) coated tablets №30


Hypersensitivity to the active substance or to other components of the drug. Hypersensitivity in history (eg bronchial asthma, angioedema, urticaria, rhinitis), allergic reactions associated with the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs. Active ulcer or history of recurrence of peptic ulcer (2 or more episodes of gastrointestinal bleeding, perforation) or peptic ulcer. Gastrointestinal bleeding or a history of perforation associated with the administration of non-steroidal anti-inflammatory drugs. Severe cardiac and / or hepatic and / or renal failure. Period after coronary artery bypass grafting (CABG). Cerebrovascular or other active form of bleeding, hemorrhagic diathesis. The third trimester of pregnancy. Breastfeeding period. Children’s age (up to 18 years).

Category: Manufacturer: India


active substance: nabumetone;
1 tablet contains nabumetone 500 mg;
Excipients: microcrystalline cellulose, corn starch, polysorbate 80, sodium lauryl sulfate, sodium starch glycolate (type A), colloidal anhydrous silica, talc, hypromellose, titanium dioxide (E 171), polyethylene glycol.
Dosage form
Coated tablets.
Pharmacological properties
The active substance of the drug – nabumetone – belongs to non-steroidal anti-inflammatory drugs (NSAIDs). Has anti-inflammatory, antipyretic, analgesic effect. The mechanism of action is associated with blockade of cyclooxygenase, which leads to disruption of arachidonic acid metabolism and decreased concentrations of prostaglandins, thromboxanes. Inhibits exudative and proliferative processes in the inflammatory focus, reduces the concentration of bradykinin and histamine, as well as increases the threshold of susceptibility to pain receptors. Hypothermic action is due to a decrease in the concentration of pyrogens in the cerebrospinal fluid and hypothalamic area, increased heat transfer (no effect on heat production).
A characteristic feature of nabumetone is the lack of effect on the gastric mucosa. A lower incidence of peptic ulcer disease, bleeding and perforation was reported compared to other NSAIDs. Has little effect on platelet aggregation caused by collagen and does not affect the bleeding time.

  • Acute and chronic osteoarthritis.
  • Rheumatoid arthritis.
  • Soft tissue rheumatism.
  • Ankylosing spondylitis.

Hypersensitivity to the active substance or to other components of the drug.
History of hypersensitivity (eg, bronchial asthma, angioneurotic edema, urticaria, rhinitis) associated with the use of acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs.
Active peptic ulcer disease or a history of gastrointestinal bleeding, perforation or peptic ulcer disease (2 or more episodes).
History of gastrointestinal bleeding or perforation associated with nonsteroidal anti-inflammatory drugs.
Severe heart and / or hepatic and / or renal failure.
Cerebrovascular or other active form of bleeding, hemorrhagic diathesis.
Use during pregnancy or breastfeeding
The safety and efficacy of nabumetone in pregnant women have not been established. Nabumetone, like other nonsteroidal anti-inflammatory drugs, can cause premature closure of the arterial duct in the fetus, the development of heart and lung defects.
The drug is contraindicated for use in the III trimester of pregnancy. The use of the drug in the I and II trimesters of pregnancy is possible when the potential benefit to the mother outweighs the potential risk to the fetus.
Breastfeeding period
The excretion of nabumetone in breast milk has not been studied. If you use the drug should stop breastfeeding.
Method of application and dosage
The drug should be used orally by adults during or after meals.
The recommended starting dose is 500 mg once daily. The recommended daily dose is 500-1 g 1 time a day before bedtime. In some cases, the dose can be increased to 1.5-2 g per day in 1 or 2 doses. The maximum daily dose is 2 g
The drug should be used for the shortest time in the lowest effective dose required to control the symptoms of the underlying disease.
The drug is not recommended for use in pediatric practice, as the safety and efficacy of nabumetone in children have not been established.
Symptoms: headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhea, disorientation, agitation, coma, drowsiness, dizziness, tinnitus, fainting, convulsions; in case of severe poisoning, acute renal failure and liver damage are possible.
Treatment: during the first hour after an overdose should use activated charcoal, gastric lavage, forced diuresis, further therapy – symptomatic. Liver and kidney function should be closely monitored. The patient should be closely monitored for at least 4 hours after an overdose.

Side effects:

  • From the blood and lymphatic system: thrombocytopenia, leukopenia, agranulocytosis, granulocytopenia, neutropenia, aplastic anemia, hemolytic anemia.
  • From the immune system: hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions.
  • From the psyche: confusion, nervousness, insomnia, depression, hallucinations.
  • From the nervous system: drowsiness, dizziness, headache, paresthesia, agitation, aseptic meningitis.
  • From the eyes: visual disturbances, optic neuritis.
  • From the organs of hearing and vestibular apparatus: tinnitus, hearing impairment.
  • From the cardiovascular system: heart failure, arrhythmias, hypertension, hypotension, edema, vasculitis.
  • From the respiratory system, chest and mediastinum: shortness of breath, respiratory disorders, nosebleeds, interstitial pneumonitis, asthma, increased asthma, bronchospasm.
  • From the digestive tract: diarrhea, constipation, dyspepsia, gastritis, nausea, abdominal pain, flatulence, ulcers of the mucous membrane of the digestive tract, gastrointestinal bleeding, exacerbation of ulcerative colitis and Crohn’s disease, gastrointestinal disorders, melena, vomiting, heartburn, stomatitis, dry mouth, pancreatitis.
  • From the hepatobiliary system: liver failure, jaundice.
  • From the urinary system: renal failure, nephrotic syndrome, interstitial nephritis, dysuria.
  • From the musculoskeletal system and connective tissue: myopathy.
  • Skin and subcutaneous tissue disorders: rash, pruritus, photosensitization, urticaria, increased sweating, bullous reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, angioneurotic edema, pseudoporrhoea.
  • From the reproductive system and mammary glands: metrorrhagia.
  • General disorders: edema, asthenia, fatigue, malaise.

Expiration date
2 years.
Storage conditions
Store at a temperature not exceeding 25 ° C. Keep out of reach of children.